|
EGFR Inhibitor ERAS-801 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: ERAS 801, ERAS-801, ERAS801
Los Angeles, California1 trial
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
UCLA / Jonsson Comprehensive Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.